NICO logo

NICO

CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer

NICO

CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer
Funding Bristol Myers Squibb
Portfolio Cancer
Interventions Medicine
Randomised No
Status Recruiting
Start Date 08-May-2019

This study is looking at adding nivolumab to chemoradiotherapy or radiotherapy for cancer of the mouth.
It is for people whose cancer has spread to nearby tissues or lymph nodes but hasn’t spread elsewhere in the body.
The usual treatment for mouth cancer, is Surgery. After Surgery, you might have radiotherapy alone or with chemotherapy (chemoradiotherapy). This is to kill any cancer cells that might have been left behind. And lower the risk of the cancer coming back.

But sometimes the cancer does come back. So, doctors are looking for ways to improve treatment. In this study, they are looking at a drug called nivolumab.

Nivolumab is a type of immunotherapy. It stimulates the body’s immune system to fight cancer cells.

The main aims of this study are to find out:
• whether adding nivolumab to usual treatment prevents the cancer coming back
• more about the side effects
• how it affects quality of life

Publications

  • n/a